BioCentury
ARTICLE | Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo pairs its ALS therapy with an imaging probe to ensure the small molecule binds HDAC6 in the brain

March 20, 2020 9:06 PM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Eikonizo Therapeutics Inc.

BCIQ Target Profiles

Histone deacetylase 6 (HDAC6)

Next in Daily Edition for March 20, 2020